ORIGINAL RESEARCH article

Front. Genet., 06 April 2023

Sec. Genetics of Common and Rare Diseases

Volume 14 - 2023 | https://doi.org/10.3389/fgene.2023.1125473

Genetic variations in the DYNC2H1 gene causing SRTD3 (short-rib thoracic dysplasia 3 with or without polydactyly)

  • WC

    Wenqi Chen 1†

  • YL

    Yazhou Li 2†

  • JZ

    Jing Zhang 1

  • YY

    Yufan Yuan 1

  • DS

    Donglan Sun 1

  • JY

    Jiayu Yuan 2

  • KY

    Kai Yang 3

  • YL

    Ying Liang 4*

  • QG

    Qing Guo 1*

  • 1. Prenatal Diagnosis Center, Shijiazhuang Obstetrics and Gynecology Hospital, Key Laboratory of Maternal and Fetal Medicine of Hebei Province, Shijiazhuang, Hebei, China

  • 2. Department of Pediatric Orthopaedic, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, China

  • 3. Prenatal Diagnosis Center, Beijing Obstetrics and Gynecology Hospital, Beijing Maternal and Child Healthcare Hospital, Capital Medical University, Beijing, China

  • 4. Reproductive Medicine Center, Shijiazhuang Obstetrics and Gynecology Hospital, Shijiazhuang, Hebei, China

Abstract

Background and aims: Short-rib thoracic dysplasia 3 with or without polydactyly (SRTD3) represents a type of severe fetal skeletal dysplasia (SD) characterized by shortened limbs, narrow thorax with or without polydactyly, which is caused by the homozygous or compound heterozygous mutations in the DYNC2H1 gene. SRTD3 is a recessive disorder, identification of the responsible genetic variation would be beneficial to an accurate prenatal diagnosis and well-grounded counseling for the affected families.

Material and methods: Two families having experienced recurrent fetal SDs were recruited and submitted to a multiplatform genetic investigation. Whole-exome sequencing (WES) was performed with samples collected from the probands. Sanger sequencing and fluorescent quantitative PCR (qPCR) were conducted as validation assays for suspected variations.

Results: WES identified two compound heterozygous variations in the DYNC2H1(NM_001080463.2) gene, namely c.2386C>T (p.Arg796Trp) and c.7289T>C (p.Ile2430Thr) for one; and exon (64–83)del and c.8190G>T (p.Leu2730Phe) for the other, respectively. One variant in them, exon (64–83)del, was novelly identified.

Conclusion: The study detected two compound heterozygous variation in DYNC2H1 including one novel deletion: exon (64–83) del. Our findings clarified the cause of fetal skeletal dysplasia in the subject families, provided guidance for their future pregnancies, and highlighted the value of WES in diagnosis of skeletal dysplasia with unclear prenatal indications.

Introduction

Short-rib thoracic dysplasia (SRTD) with or without polydactyly is an umbrella term of a group of genetically heterogeneous skeletal dysplasias consistent with the autosomal recessive (AR) inheritance pattern. SRTDs are characterized by short ribs, short limbs, constricted thoracic cage, a ‘trident’ appearance of the acetabular roof and anomalies in kidney, heart, liver, pancreas, genitalia and intestine (; ; ; ; ; ). Currently, SRTD are classified into the categories of short-rib thoracic dysplasia with or without polydactyly type 1–21 (SRTD1-21) (Table 1).

TABLE 1

PhenotypeLocationPhenotypeMIM numberGeneGene MIM numberInheritance
SRTD115q13208500SRTD1208500AR
SRTD23q25.33611263IFT80611177AR
SRTD311q22.3613091DYNC2H1603297AR,DR
SRTD42q24.3613819TTC21B612014AR
SRTD54p14614376WDR19608151AR
SRTD64q33263520NEK1604588AR,DR
SRTD72p24.1614091WDR35613602AR
SRTD87q36.3615503WDR60615462AR
SRTD916p13.3(266920)IFT140614620AR
SRTD102p23.3615630IFT172607386AR
SRTD119q34.11615633WDR34613363AR
SRTD12not mapped269860SRTD12269860AR
SRTD135q23.2616300CEP120613446AR
SRTD1414q23.1616546KIAA0586610178AR
SRTD152p21617088DYNC2LI1617083AR
SRTD1620q13.12617102IFT52617094AR
SRTD173q29617405TCTEX1D2617353AR
SRTD1814q24.3617866IFT43614068AR
SRTD1912q24.11617895IFT81605489AR
SRTD204q28.1617925INTU610621AR
SRTD2117p13.1619479KIAA0753617112AR

SRTD are classified into the categories of SRTD1-21.

The short-rib thoracic dysplasia 3 with or without polydactyly (SRTD3; OMIM #613091) refers to a rare subtype of SRTDs, characterized by the constricted thoracic cage, shortened limbs, and associated visceral abnormalities with or without polydactyly. SRTD3 belongs to the “ciliopathies with major skeletal involvement” conditions according to the revised consensus workshop (), and is caused by homozygous or compound heterozygous mutations in the DYNC2H1 gene (dynein, cytoplasmic 2, heavy chain 1; OMIM #603297), which encodes a component of the cytoplasmic dynein complex (; ). This complex is associated with the ciliary intraflagellar transport (IFT), an evolutionarily conserved process that is necessary for ciliogenesis and plays an important role in Hedgehog (Hh), Wnt, Platelet-derived growth factor (PDGF), Notch, G-Protein coupled receptor (GPCR), Mammalian target of rapamycin (mTOR), Transforming growth factor beta (TGF-β) and Calcium signaling pathways (; ).

In general, SRTD3 is lethal in the neonatal period due to respiratory insufficiency secondary to the severely restricted thoracic cage, whereas other SRTD subtypes are compatible with life (; ). Although prenatal ultrasonography could detect the skeletal abnormalities of SRTD3, this condition was often difficult to be precisely diagnosed before birth. Since SRTD3 is a recessive disorder, identification of the responsible genetic variation would be beneficial to an accurate prenatal diagnosis and well-grounded counseling for the affected families.

In the present study, two families with experiences of multiple adverse gestations including recurrent fetal skeletal dysplasias were recruited. Prenatal ultrasonography examination and genetic detection were conducted to identify the causes of these manifestations in affected fetuses.

Materials and methods

Subjects

Two unrelated cases were recruited between March 2020 and April 2021 at the Prenatal Diagnosis Center, Shijiazhuang Obstetrics and Gynecology Hospital. A comprehensive prenatal ultrasonic examination was conducted on the patients. We carried out a thorough clinical survey. Subsequently, the peripheral blood samples of trio family members in the two pedigrees were collected for the following genetic detection. The studies involving human participants were reviewed and approved by The Ethics Committee of Shijiazhuang Obstetrics and Gynecology Hospital.

Genomic DNA extraction

Amniocentesis was performed to obtain the fetal cell samples, along with 3 ml of peripheral blood collected from the parents using BD Vacutainer™ tubes (BD Biosciences, New Jersey, United States). Genomic DNA was extracted with the QIAamp DNA Blood Mini-Kit (Qiagen Sciences, New York, United States), and the DNA quality was validated by 1% agarose gels and the Qubit® 2.0 Flurometer (Life Technologies, CA, United States).

Whole-exome sequencing

WES was performed by MyGenomics, Inc. (Changping, Beijing, China) as described in our previous study (). Briefly, the enrichment of the exonic region sequences was conducted by the Sure Select Human Exon Sequence Capture Kit (Agilent, United States). The sequencing library was quantified using the Illumina DNA Standards and Primer Premix Kit (Kapa Biosystems, United States), and was massively parallel-sequenced using the Illumina Novaseq6000 platform. After sequencing and filtering out the low-quality reads, the high-quality data (with general quality level Q30 reads >89%) was aligned to the human genome reference sequence [hg19] using Burrows-Wheeler Aligner tool. The third-party software GATK (https://softw are.broad institute.org/gatk/) and the Verita Trekker® Variants Detection system (Berry Genomics, China) were employed for variant calling. Variants with lower quality (read depth<10x, allele fraction<30%) were eliminated. The variations were identified by sequence alignment with the NCBI Reference Sequence (NG_016423.2, NP_001073932.1, NM_001080463.2) using Chromas v2.33. The pathogenicity of the identified variants was then assessed according to the common guidelines issued by the American Association of Medical Genetics and Genomics (ACMG) () referring to multiple databases (1000g2015aug_eas, https://www.internationalgenome.org/; ExAC_EAS, http://exac.broadinstitute.org; gnomAD_exome_EAS, http://gnomad.broadinstitute.org/; HGMD®: Human Gene Mutation Database Professional v.2021.10) with the Enliven® Variants Annotation Interpretation (Berry Genomics, China) system.

Validation experiments

The suspected diagnostic variants were validated by Sanger sequencing using ABI 3730 Automated Sequencer (Applied Biosystems, United States) according to the manufacturer’s protocol. Fluorescent quantitative PCR (qPCR) was also carried out to verify the suspected deletion variant identified in Case 2.

Analysis of missense variants

The evolutionary conservatism of amino acid (AA) residues affected by specific missense variants was analyzed using UGENE (http://ugene.net/) with default parameters.

Structural analysis

Referring to the crystal structure of 6rla. 1. A () protein, the DYNC2H1 protein structures at 2241–2520 and 2611–2880 regions were constructed by Swiss-model program. The Swiss-Pdb Viewer program was referred to modeling the wild-type (WT) and DYNC2H1: p. Ile2430Thr and p. Leu2730Phe mutant models of DYNC2H1 protein segments. The molecular dynamics (MD) prediction analysis was generated by GROMACS (version 2020.6) (). We carried out 60 ns MD simulations on the DYNC2H1-WT, DYNC2H1-Ile2430Thr, and DYNC2H1-Leu2730Phe models. The CHARMM36 force field was applied to add hydrogen atoms and N-terminal and C-terminal patches to the models (). The wild type or the mutant structure of the protein was immersed in cubic boxes which contains water and placed at least 1.0 nm from the box edge. Na+ and Cl− ions were used for neutralization. The MD simulations were performed at a temperature of 300K for 60 ns after energy minimization, equilibration. The following GROMACS distribution programs were used in MD trajectories: gmxrms, gmxrmsf, gmx gyrate, gmxsasa, and gmxhbond. These MD analyses generated parameters values for root-mean-square deviation (RMSD), root-mean-square fluctuation (RMSF), radius of gyration, solvent accessible surface area (SASA), and number of h-bonds.

Results

Clinical manifestations

Case 1. A 32-year-old woman was referred to our center in March 2021 for previous multiple adverse gestations, when she was at the 17th+gestational week. Her husband was 31 years old, with no consanguineous relation to her. Based on the medical record and her personal dictation, we combed through the couple’s complete medical history and illustrated the pedigree in a diagram (Figure 1A). They had 3 previous pregnancies: in October 2016 and July 2017, they went through one spontaneous abortion and one stillbirth, respectively; in November 2018, the prenatal sonography revealed a 22-week fetus with short limbs and a narrow chest, which was diagnosed as thanatophoric dwarfism. That pregnancy was subsequently terminated.

FIGURE 1

In 2020, they had the 4th gestation, and the serological screening and NIPT (non-invasive prenatal testing) results were normal. At the 17th week, ultrasonic examination and MRI revealed that the fetus had extremely short limbs and small, bell-shaped chest, short ribs, rhizomelic shortening in all extremities (Figures 1B–E). Prenatal ultrasound did not identify abnormalities in the brain, heart, kidneys, or liver. No exposure history to tobacco smoke, alcohol, ir-radiation, or infectious diseases during the pregnancy were admitted. Pregnancy termination was performed at 22 gestational weeks with informed consent. Afterwards, X-ray imaging result demonstrated that the fetus had a narrow thorax and short limbs, but no polydactyly (Figure 1F). And whole-exome sequencing (WES) was introduced afterwards.

Case 2. A 31-year-old pregnant woman was referred to our center in April 2021. Her husband and her were non-consanguineous. The pedigree diagram was depicted in Figure 2A: in November 2018, a fetus was diagnosed with constricted thoracic cage, extremely shortened tubular bones and bowing of long bones, and then aborted at 12th week; in April 2021, ultrasonography revealed that their second fetus had extremely short limbs at the 13th week (Figures 2B, C). No brain, heart, kidney, or liver abnormality was found by prenatal ultrasonography. The woman denied to be exposed to tobacco smoke, alcohol, radiation or infectious diseases during pregnancy. After informed consent by the couple, genetic analysis including WES was also performed after induction.

FIGURE 2

Genetic variations

Karyotyping by G-bandeding showed that the results of the fetuses in both Case1 and 2 were normal, and array-CGH analysis did not reveal any genomic abnormality associated with known microdeletion or microduplication syndromes, either. On the other hand, according to the WES results, the two fetuses were recognized as positive with compound heterozygous variation in the DYNC2H1 gene. To be specific, Proband 1 (II-4 in Case 1) carried two heterozygous missense variants, namely c.2386C>T (p.Arg796Trp) and c.7289T>C (p.Ile2430Thr) (Figures 1G, H); while Proband 2 (II-2 in Case 2) carried an exonic deletion, exon (64–83)del, and a missense variant, c.8190G>T (p.Leu2730Phe) (Figure 2G). qPCR validation confirmed the one copy loss of 64–83 exons in DYNC2H1 of Proband 2 (Figure 2D). Validation with Sanger sequencing and qPCR demonstrated that the variants these probands carried were inherited from their asymptomatic heterozygous carrier parents, respectively (Figures 1G, H; Figures 2D–G). The location of each variant was illuminated in the gene and peptide diagrammatic sketches (Figure 3A).

FIGURE 3

Conservatism analysis of missense variants

In this study, three missense variants were detected, which were DYNC2H1: c.2386C>T (p.Arg796Trp), c.7289T>C (p.Ile2430Thr) and c.8190G>T (p.Leu2730Phe). We analyzed the evolutionary conservatism of AA residues they affected. Results indicated that all three AAs maintained highly conserved among species (Figure 3B).

Structural analysis and molecular dynamics simulation

To investigate the intramolecular effect of these missense variants, we performed structural analysis and MD simulation. Due to the structural inaccuracy of the region where p. Arg796Trp was located, we only analyzed the DYNC2H1 protein structures at 2241–2520 region (violet part in Figure 4A) and 2611–2880 region (orange part in Figure 4A), where p. Ile2430Thr and p. Leu2730Phe were located.

FIGURE 4

The results demonstrated that the Ile2430Thr variant affected the hydrogen bonding between amino acids inside the protein. Particularly, in the wild-type, Ile2430 formed hydrogen bonds with Val2290 residues, with the hydrogen bond length of 2.9Å; while the Ile2430Thr mutant formed a hydrogen bond with Val2290 with a hydrogen bond length of 1.9Å (Figures 4B–E; 4C and 4E are local amplifications of 4B and 4D, respectively). As for the MD results, first, the Thr2430 mutant formed more hydrogen bonds with other amino acids in the protein than the wild-type residue Ile2430 (Figure 4F); for the total number of hydrogen bonds inside the models within 60ns, the amount of Ile2430Thr mutant was more than that of the wild-type (Figure 4G). Besides, the Ile2430Thr variant resulted in a change in secondary structure around 2350th and 2400th residue (Figures 4H, I). Specifically, in wild-type, the secondary structure at 2350 position was dominated by BEND; yet in the mutant, the secondary structure alternated between BEND and TURN and was dominated by TURN. In wild-type, the secondary structure at 2400 position was dominated by BEND; yet in the mutant, the secondary structure alternated between BEND and TURN and was dominated by TURN. Finally, the Ile2430Thr variant resulted in decreased changes in protein structure (Figure 4J), decreased flexibility of amino acids in protein (Figure 4K), increased protein compactness (Figure 4L), and decreased surface area accessible to protein solvent (Figure 4M).

Structural result demonstrated that Leu2730Phe variant affected the hydrogen bonding between amino acids inside the protein. Particularly, Leu2730 and Phe2730 both formed hydrogen bonds with Ile2726 and Lys2802 residues, yet in the Leu2730Phe mutant the hydrogen bond length is shorter than that in the wild-type (Figures 5A–D; 5B and 5D are local amplifications of 5A and 5C, respectively). As for the MD results, there was no difference between Leu2730 and Phe2730 in the number of hydrogen bonds formed with other amino acids in the protein (Figure 5E); for the number of total hydrogen bonds inside the models within 60ns, the amount of Leu2730Phe mutant was more than that of the wild-type (Figure 5F). In wild-type, the secondary structure at 2690 position was dominated by H-helix; yet in the mutant, the secondary structure showed a high rate of BEND and TURN (Figures 5G, H). The Leu2730Phe mutation has little influence on RMSD, RMSF, Gyrate, and SASA (Figures 5I–L).

FIGURE 5

Discussion

SRTD3 refers to a sort of autosomal recessive skeletal condition characterized by shortened limbs, narrow thorax, with or without polydactyly, non-skeletal involvement can include cleft lip/palate as well as anomalies of major organs such as the brain, eye, heart, kidneys, liver, pancreas, intestines, and genitalia (). The prenatal ultrasound features of SRTD3 are similar to other skeletal diseases, so it is difficult to establish a definite diagnosis, which proposes a challenge in prenatal diagnosis and management on fetuses with similar early manifestations.

In this study, two families with experiences of multiple adverse gestations including recurrent fetal skeletal dysplasia were enrolled. Ultrasonography detection of the two fetuses revealed skeletal abnormalities characteristics of SRTD3, including extreme shortness of the limbs, and narrow thorax. Signs of polydactyly and non-skeletal symptoms were not noted in the two cases. In Case 1, WES detected a compound heterozygous variation in the DYNC2H1 gene with two variants, c.2386C>T and c.7289T>C. The allele frequencies of c.2386C>T (p.Arg796Trp) and c.7289T>C (p.Ile2430Thr) in gnomAD database were 2.3822e-05 and 9.39391e-06 respectively. In agreement with autosomal-recessive segregation, the parents were heterozygous for these two variants, respectively: the father carried the heterozygous c.2386C>T variant while the mother carried the c.7289T>C variant. The c.2386C>T variant caused a replacement of Arg796 residue by a Trp amino acid, and c.7289T>C caused a substitution of Ile2430 residue by a Thr amino acid. According to the variant interpretation criteria by ACMG, c.2386C>T (p.Arg796Trp), and c.7289T>C (p.Ile2430Thr) variants were classified as VUS, with the evidence of PM2+PP3. The c.2386C>T (p.Arg796Trp) and c.7289T>C (p.Ile2430Thr) variants were predicted to be pathogenic by the SIFT algorithm, Mutation Taster, and PolyPhen-2.

In Case 2, a compound heterozygous variation in DYNC2H1 gene with 2 variants, exon (64–83) del and c.8190G>T, was identified and confirmed. The former one was a novel variant not indexed in the databases of 1000G (https://www.internationalgenome.org/), gnomAD (http://gnomad.broadinstitute.org/), ExAC_EAS (http://exac.broadinstitute.org) and Berry Genomics inhouse database, which expanded the variation spectrum of DYNC2H1 gene. The allele frequencies of c.8190G>T (p.Leu2730Phe) in the databases of EXAC and gnomAD were 2.7e-05 and 1.6 e-05 respectively. Consistent with autosomal-recessive segregation, the parents were heterozygous for the identified mutations: the father carried exon (64–83)del, while the mother carried c.8190G>T. According to the variant interpretation criteria by ACMG, the exon (64–83)del variant was classified as pathogenic, with the evidence of PVS1+PM2. According to the variant interpretation criteria by ACMG, the c.8190G>T (p.Leu2730Phe) variant was classified as VUS, with the evidence of PM2+PP3. The c.8190G>T variant caused a replacement of Leu2730 residue by a Phe amino acid, and this variant was predicted to be pathogenic by the SIFT algorithm, Mutation Taster, and PolyPhen-2. The three residues affected by c.2386C>T (p.Arg796Trp), c.7289T>C (p.Ile2430Thr) and c.8190G>T (p.Leu2730Phe) variants maintained conserved across species, which strongly supports the pathogenicity of these variants. The pathogenicity and ACMG classification of all the variants identified in DYNC2H1 were shown in Table 2.

TABLE 2

No.Genomic coordinatesReferences base(s)Variant base(s)HGVS† descriptionACMG
1chr11:102980496–102980496AC193A>CVUS
2chr11: 102980498–102980498GT195G>TLikely Pathogenic
3chr11: 102984382–102984383TA313_314delATLikely Pathogenic
4chr11:102984397–102984397CG327C>GPathogenic
5chr11:102984407–102984407CT337C>TLikely Pathogenic
6chr11: 102985918–102985918CA515C>AVUS
7chr11: 102985938–102985938TG535T>GVUS
8chr11:102985939–102985939GA536G>APathogenic
9chr11: 102987300–102987302AGTAAA624_625delGTinsAAPathogenic
10chr11: 102987302–102987302TA625T>APathogenic
11chr11:102987417–102987417GA740G>AVUS
12chr11:102988358–102988358AG767-2A>GPathogenic
13chr11:102988465–102988465GT872G>TVUS
14chr11:102988533–102988533TC940T>CVUS
15chr11:102988581–102988581CT988C>TLikely Pathogenic
16chr11:102991188–102991188AG1012A>GVUS
17chr11:102991254–102991254CT1078C>TPathogenic
18chr11:102991434–102991434CT1151C>TLikely Pathogenic
19chr11:102991693–102991693CT1288C>TVUS
20chr11:102991694–102991694GA1289G>AVUS
21chr11:102991711–102991711GT1306G>TPathogenic
22chr11:102991767–102991767T1360+2delTPathogenic
23chr11:102992161–102992161TG1421T>GVUS
24chr11:102992166–102992166G1427delGLikely Pathogenic
25chr11:102992224–102992224AG1484A>GVUS
26chr11:102993672–102993672TC1604T>CVUS
27chr11:102993723–102993726GTTT1657_1660delTTGTPathogenic
28chr11:102995926–102995926CT1759C>TLikely Pathogenic
29chr11:102996011–102996016TTATTC1847_1852delTTCTTALikely Pathogenic
30chr11:102996022–102996022CT1855C>TPathogenic
31chr11:102999730–102999730TA1949T>ALikely Pathogenic
32chr11:102999734–102999734GA1953G>ALikely Pathogenic
33chr11:103004369–103004369T2040dupTPathogenic
34chr11:103004417–103004417AC2087A>CVUS
35chr11:103005113–103005113GA2170G>AVUS
36chr11:103006243–103006243TG2225T>GLikely Pathogenic
37chr11:103006359–103006359TG2341T>GLikely Pathogenic
38chr11:103006444–103006444TG2346-5T>GLikely Pathogenic
39chr11:103006488–103006488C2386delCPathogenic
40chr11:103006488–103006488GA2386C>TVUS
41chr11:103006497–103006497AG2394A>GVUS
42chr11:103006498–103006500TAT2398_2400delTATVUS
43chr11:103006546–103006546GC2443G>CVUS
44chr11:103006652–103006652TA2549T>ALikely Pathogenic
45chr11:103006678–103006678GA2574 + 1G>APathogenic
46chr11:103013996–103013996GA2575-1G>ALikely Pathogenic
47chr11:103014034–103014034TC2612T>CVUS
48chr11:103018547–103018549ACTAG2750_2751delCTinsGLikely Pathogenic
49chr11:103018617–103018617GC2818 + 1G>CPathogenic
50chr11:103019205–103019205AG2819-14A>GVUS
51chr11:103022910–103022910CT2992C>TLikely Pathogenic
52chr11:103022977–103022977TG3059T>GPathogenic
53chr11:103023013–103023013A3095delAPathogenic
54chr11:103024028–103024028AG3097-4A>GBenign
55chr11:103024068–103024068CT3133C>TLikely Pathogenic
56chr11:103024187–103024187AC3252A>CVUS
57chr11:103024190–103024190A3262dupAPathogenic
58chr11:103025179–103025179GA3303-1G>ALikely Pathogenic
59chr11:103025208–103025208GA3331G>AVUS
60chr11:103025230–103025230G3353delGPathogenic
61chr11:103025335–103025335GA3458G>AVUS
62chr11:103025423–103025423GA3459-1G>APathogenic
63chr11:103026124–103026124TG3638T>GVUS
64chr11:103026168–103026168CA3682C>AVUS
65chr11:103026180–103026180GA3694G>AVUS
66chr11:103026205–103026205TC3719T>CVUS
67chr11:103027219–103027219GC3847G>CVUS
68chr11:103027444–103027444CT4072C>TVUS
69chr11:103027445–103027445GA4073G>ALikely Pathogenic
70chr11:103029413–103029413AG4135A>GVUS
71chr11:103029438–103029438AGTCACAAC4162_4170dupGTCACAACALikely Pathogenic
72chr11:103029637–103029637AG4261-2A>GLikely Pathogenic
73chr11:103029645–103029645CT4267C>TPathogenic
74chr11:103029703–103029703GA4325G>AVUS
75chr11:103029729–103029729CT4351C>TLikely Pathogenic
76chr11:103031700–103031700TC4418T>CLikely Pathogenic
77chr11:103031737–103031737T4458delTPathogenic
78chr11:103031764–103031768TAATG4484_4488delATGTALikely Pathogenic
79chr11:103033818–103033818GA4553G>ALikely Pathogenic
80chr11:103033875–103033875AG4610A>GVUS
81chr11:103036640–103036640CT4625C>TLikely Pathogenic
82chr11:103036714–103036714CG4699C>GLikely Pathogenic
83chr11:103039541–103039541TA4820T>ALikely Pathogenic
84chr11:103039630–103039630GT4909G>TVUS
85chr11:103039685–103039685AG4964A>GLikely Pathogenic
86chr11:103040955–103040955CT5087C>TLikely Pathogenic
87chr11:103040997–103040997TA5129T>ALikely Pathogenic
88chr11:103041020–103041020GT5151 + 1G>TLikely Pathogenic
89chr11:103041639–103041639CT5176C>TPathogenic
90chr11:103041680–103041680T5220delTLikely Pathogenic
91chr11:103043839–103043839TG5363T>GVUS
92chr11:103043994–103043994TA5520_5521dupATLikely Pathogenic
93chr11:103044036–103044036TC5558 + 2T>CPathogenic
94chr11:103044837–103044837C5612delCPathogenic
95chr11:103046970–103046971AA5682_5683delAAPathogenic
96chr11:103047080–103047080TA5791T>AVUS
97chr11:103047082–103047082GC5793G>CVUS
98chr11:103048286–103048286TA5876T>ALikely Pathogenic
99chr11:103048330–103048330GT5920G>TPathogenic
100chr11:103048334–103048334T5925delTPathogenic
101chr11:103048369–103048369AG5959A>GLikely Pathogenic
102chr11:103048381–103048381AT5971A>TPathogenic
103chr11:103048382–103048382TA5972T>ALikely Pathogenic
104chr11:103048393–103048393GA5983G>APathogenic
105chr11:103048394–103048394CT5984C>TLikely Pathogenic
106chr11:103048445–103048445CT6035C>TVUS
107chr11:103048453–103048453CT6043C>TLikely Pathogenic
108chr11:103048454–103048454GA6044G>AVUS
109chr11:103048457–103048457AG6047A>GLikely Pathogenic
110chr11:103048526–103048526GA6116G>ALikely Pathogenic
111chr11:103049776–103049776GC6161G>CLikely Pathogenic
112chr11:103049821–103049821TC6206T>CVUS
113chr11:103049880–103049880AG6265A>GLikely Pathogenic
114chr11:103049886–103049886AG6271A>GVUS
115chr11:103049959–103049959TA6344T>AVUS
116chr11:103052525–103052525GT6387G>TVUS
117chr11:103055609–103055609GA6478-16G>AVUS
118chr11:103055627–103055627TA6480T>ALikely Pathogenic
119chr11:103055692–103055692GA6545G>ALikely Pathogenic
120chr11:103055698–103055698AT6551A>TLikely Benign
121chr11:103055709–103055709TC6562T>CLikely Pathogenic
122chr11:103055721–103055721CT6574C>TLikely Pathogenic
123chr11:103055735–103055737TGG6591_6593delTGGVUS
124chr11:103055761–103055761GA6614G>APathogenic
125chr11:103055779–103055779AT6632A>TVUS
126chr11:103056969–103056969AG6634-2A>GPathogenic
127chr11:103057016–103057016AG6679A>GVUS
128chr11:103057146–103057146GA6809G>AVUS
129chr11:103057171–103057171GT6834G>TVUS
130chr11:103057194–103057194CT6857C>TVUS
131chr11:103057203–103057203TC6866T>CLikely Pathogenic
132chr11:103057220–103057220TC6883T>CLikely Pathogenic
133chr11:103058085–103058085GA6910G>ALikely Pathogenic
134chr11:103058253–103058253GT7078G>TVUS
135chr11:103058260–103058260AG7085A>GLikely Pathogenic
136chr11:103058287–103058287CT7112C>TLikely Pathogenic
137chr11:103058304–103058304TG7129T>GVUS
138chr11:103059233–103059233CT7148C>TVUS
139chr11:103059353–103059353CA7268C>ALikely Pathogenic
140chr11:103059361–103059361CT7276C>TVUS
141chr11:103059362–103059362GT7277G>TLikely Pathogenic
142chr11:103059374–103059374AG7289T>CVUS
143chr11:103060490–103060490GT7382G>TVUS
144chr11:103060517–103060517CG7409C>GLikely Pathogenic
145chr11:103060548–103060548AG7437 + 3A>GVUS
146chr11:103062244–103062244AG7438-2A>GPathogenic
147chr11:1103062249–103062249CT7441C>TPathogenic
148chr11:103062250–103062250GA7442G>AVUS
149chr11:103062294–103062294CT7486C>TVUS
150chr11:103062333–103062333TC7525T>CLikely Pathogenic
151chr11:103062347–103062347AT7539A>TVUS
152chr11:103062846–103062846GC7561G>CVUS
153chr11:103062862–103062862TG7577T>GLikely Pathogenic
154chr11:103062879–103062879CT7594C>TLikely Pathogenic
155chr11:103062928–103062928TC7643T>CLikely Pathogenic
156chr11:103062948–103062948GA7663G>ALikely Pathogenic
157chr11:103068671–103068671AG7718A>GVUS
158chr11:103068724–103068732CCATTACCT7774_7782delTTACCTCCALikely Pathogenic
159chr11:103068737–103068737AG7784A>GLikely Benign
160chr11:103070000–103070000TC7883T>CVUS
161chr11:103070036–103070036TC7919T>CVUS
162chr11:103070042–103070042GC7925G>CVUS
163chr11:103070062–103070062GT7945G>TLikely Pathogenic
164chr11:103070083–103070083CT7966C>TLikely Pathogenic
165chr11:103070084–103070084GA7967G>AVUS
166chr11:103070084–103070084GT7967G>TLikely Pathogenic
167chr11:103070098–103070098CT7981C>TVUS
168chr11:103070101–103070101CT7984C>TPathogenic
169chr11:103070102–103070102GA7985G>ALikely Pathogenic
170chr11:103070104–103070104AC7987A>CVUS
171chr11:103070129–103070129TC8012T>CLikely Pathogenic
172chr11:103070167–103070167GT8050G>TPathogenic
173chr11:103070179–103070179A8063delALikely Pathogenic
174chr11:103070187–103070187CG8070C>GLikely Pathogenic
175chr11:103070194–103070194GT8077G>TVUS
176chr11:103070831–103070831CA8145C>APathogenic
177chr11:103070876–103070876-CA8190G>TVUS
178chr11:103070883–103070883GT8197G>TLikely Pathogenic
179chr11:103074471–103074471T8283delTPathogenic
180chr11:103074506–103074506GA8311 + 1G>APathogenic
181chr11:103075552–103075552AT8313A>TVUS
182chr11:103075578–103075578TC8339T>CVUS
183chr11:103075628–103075636CCAGCTTTG8390_8398delCAGCTTTGCVUS
184chr11:103075673–103075673T8434delTPathogenic
185chr11:103080607–103080607AG8457A>GVUS
186chr11:103080662–103080662CT8512C>TPathogenic
187chr11:103080677–103080677A8534delAPathogenic
188chr11:103082568–103082568G8590delGPathogenic
189chr11:103082595–103082595AG8617A>GVUS
190chr11:103082669–103082669GA8691G>AVUS
191chr11:103086484–103086484TC8729T>CLikely Pathogenic
192chr11:103086520–103086521GT8769_8770delGTPathogenic
193chr11:103091415–103091415CT9010C>TVUS
194chr11:103091449–103091449AG9044A>GLikely Pathogenic
195chr11:103091450–103091450TG9045T>GLikely Pathogenic
196chr11:103093704–103093704GA9242G>AVUS
197chr11:103093816–103093816GA9353 + 1G>APathogenic
198chr11:103104887–103104887CT9565C>TPathogenic
199chr11:103106471–103106471AG9638A>GVUS
200chr11:103106494–103106494CT9661C>TVUS
201chr11:103107157–103107157AG9710-2A>GPathogenic
202chr11:103107208–103107212GAAAA9760_9764delAAAAGPathogenic
203chr11:103107263–103107263TA9814T>ALikely Benign
204chr11:103107266–103107266CT9817C>TPathogenic
205chr11:103112255–103194718EX64-EX83 DelLikely Pathogenic
206chr11:103112272–103112272CG9836C>GPathogenic
207chr11:103114423–103114423GA9842G>AVUS
208chr11:103114425–103114425CT9844C>TPathogenic
209chr11:103114446–103114446GA9865G>ALikely Pathogenic
210chr11:103114510–103114510TC9929T>CVUS
211chr11:103116017–103116017G9977delGLikely Pathogenic
212chr11:103116062–103116062CG10022C>GVUS
213chr11:103116085–103116085CT10045C>TPathogenic
214chr11:103116103–103116103GT10063G>TPathogenic
215chr11:103116105–103116105TG10063 + 2T>GPathogenic
216chr11:103124070–103124070CT10120C>TLikely Pathogenic
217chr11:103124071–103124071GA10121G>ALikely Pathogenic
218chr11:103124076–103124076TC10126T>CLikely Pathogenic
219chr11:103124076–103124076T10130delTPathogenic
220chr11:103124113–103124113CT10163C>TLikely Pathogenic
221chr11:103124169–103124169CT10219C>TPathogenic
222chr11:103126224–103126224GA10308G>AVUS
223chr11:103126259–103126259TC10343T>CPathogenic
224chr11:103128446–103128446TC10592T>CVUS
225chr11:103128448–103128448CT10594C>TPathogenic
226chr11:103128460–103128460CT10606C>TPathogenic
227chr11:103128464–103128464CT10610C>TVUS
228chr11:103128478–103128478CT10624C>TPathogenic
229chr11:103130659–103130659TC10669T>CVUS
230chr11:103130699–103130702TATT10711_10714delTTTALikely Pathogenic
231chr11:103151092–103151092TA10732T>AVUS
232chr11:103153788–103153788CT10885C>TLikely Pathogenic
233chr11:103153789–103153789GC10886G>CVUS
234chr11:103156993–103156993CT10921C>TLikely Pathogenic
235chr11:103157009–103157009C10939delCPathogenic
236chr11:103173926–103173926TC11221T>CVUS
237chr11:103173935–103173935CT11230C>TVUS
238chr11:103173983–103173983GA11277 + 1G>ALikely Pathogenic
239chr11:103175330–103175330AG11284A>GVUS
240chr11:103175337–103175337AG11291A>GLikely Pathogenic
241chr11:103175379–103175379CT11333C>TLikely Pathogenic
242chr11:103178483–103178483CT11437C>TVUS
243chr11:103178484–103178484GA11438G>AVUS
244chr11:103178533–103178534AC11488_11489delCALikely Pathogenic
245chr11:103178538–103178538CA11492C>ALikely Pathogenic
246chr11:103182652–103182652TG11560T>GVUS
247chr11:103182710–103182710-G11618delGPathogenic
248chr11:103187334–103187337GACA11734_11737delAGACPathogenic
249chr11:103187341–103187342TT11741_11742delTTLikely Pathogenic
250chr11103191758-103191758GA11747G>AVUS
251chr11:103191861–103191861CG11850C>GPathogenic
252chr11:103270549–103270549TG12336T>GVUS
253chr11:103306683–103306683TC12400T>CVUS
254chr11:103306714–103306714CG12431C>GLikely Pathogenic
255chr11:103306743–103306743CT12460C>TLikely Pathogenic
256chr11:103325912–103325912AG12478-2A>GLikely Pathogenic
257chr11:103325921–103325924TAGA12487_12490delGATAPathogenic
258chr11:103325942–103325942CG12506C>GVUS
259chr11:103325974–103325974C12538delCLikely Pathogenic
260chr11:103326007–103326007CA12571C>AVUS
261chr11:103326024–103326024GT12587 + 1G>TLikely Pathogenic
262chr11:103327017–103327017TG12605_12606dupTGPathogenic
263chr11:103327078–103327078T12663_12664insTPathogenic
264chr11:103339363–103339363TG12716T>GVUS
265chr11:103339395–103339395TA12748T>AVUS
266chr11:103349863–103349863TC12827T>CLikely Pathogenic
267chr11:103349886–103349886AG12850A>GPathogenic
268chr11:103349893–103349893GC12857G>CVUS
269chr11:103349953–103349953GA12917G>AVUS

DYNC2H1 variants (cited from HGMD† database, in order of mutation position).

†

HGMD, The Human Gene Mutation Database (http://www.hgmd.cf.ac.uk/ac/index.php); HGVS, Human Genome Variation Society (http://www.hgvs.org/).

The DYNC2H1 protein consists of an N-terminal tail (DHC_N1), a linker domain (DHC_N2), six identifiable AAA-ATPase domains, a stalk between AAA domains 4 and 5 in the microtubule binding domain (stalk MTBD), and a conserved C-terminal domain arranged on top of the ATPase ring (). DYNC2H1 is essential for ciliogenesis and plays an important role in Hedgehog signaling events which are critical to human skeletal development (; ). DYNC2H1 encodes a subunit of cytoplasmic dynein complex, a component of IFTA involved in the retrograde transport from the ciliary tip to the basal body of the ciliary axoneme and plays a role in the generation and maintenance of mammalian cilia (). Variants in DYNC2H1 have been associated with a heterogeneous spectrum of conditions related to altered primary cilium function that often involve polydactyly, abnormal skeletogenesis, and polycystic kidneys (). indicated that DYNC2H1 missense mutations altered protein function, yet the effects might be “mild” or submorphic. hypothesized that homozygosity for two null alleles would lead to early embryonic lethality, but a series of phenotypes with various severity could result from a combination of multiple missense and null mutations. The genotype-phenotype correlation of DYNC2H1 is pending further elucidation along with larger genetic data.

The c.2386C>T variant affects the highly conserved arginine residues in the stem domain, while the c.7289T>C and the c.8190G>T missense variants are located within the ATP binding and hydrolysis domains (AAA3 and AAA4, respectively). These domains play an important regulatory role for ATP binding (). Blockage of ATP hydrolysis at AAA3 or AAA4 affects the catalytic and mechanical force production activities of dynein (). Modeling the elimination of nucleotide binding at AAA2–4 domains cytoplasmic dynein indicated a severe slowed down in the microtubule sliding activity of the protein, implying dysfunctional motor activity (). The c.7289T>C and the c.8190G>T were missense changes affecting the ATP binding and hydrolysis domains of the protein (AAA3 and AAA4, respectively), which may disrupt the motor integrity, and interfering with proper retrograde IFT activity. According to the results of structural and MD analysis, the c.7289T>C (p.Ile2430Thr) variant was most likely to significantly affect both local and global hydrogen bond formation to alter protein stability, while also disrupting the desired secondary structure of the protein, thereby disrupting the binding of the protein to ATP. However, the c.8190G>T (p.Leu2730Phe) variant has less influence on the molecular dynamics. Further functional experiments are necessary, not only to clarify the effects of each variant on the protein itself, but also to understand the mechanistically contributes to the pathology seen in the skeletal ciliopathies.

For any future pregnancy of the couples in this study, the recurrent risk of SRTD3 condition would be 25%. Given such circumstances, the couples were informed of reproductive options such as prenatal testing and preimplantation genetic diagnosis (PGD). Proper genetic counseling for the affected family is essential in the case of rare genetic diseases. Furthermore, parenteral genetic screening/diagnosis is the best strategy for managing this disease, which currently has no therapy (; ; ). Reporting additional cases associated with this gene would help identify genotype–phenotype correlations and lead to clinical trials in the future ().

In summary, this study detected two compound heterozygous variation in DYNC2H1 including one novel deletion: exon (64–83)del. Our findings clarified the cause of fetal skeletal dysplasias in the subject families, provided guidance for their future pregnancies, and highlighted the value of WES in diagnosis of skeletal dysplasia with unclear prenatal indications.

Statements

Data availability statement

The datasets presented in this study can be found in online repositories. The sequencing results have been deposited to the Figshare repository and can be accessed via the following links: https://doi.org/10.6084/m9.figshare.21738650.v3 and https://doi.org/10.6084/m9.figshare.21738068.v4.

Ethics statement

The studies involving human participants were reviewed and approved by Shijiazhuang Obstetrics and Gynecology Hospital. The patients/participants provided their written informed consent to participate in this study.

Author contributions

WC wrote the first draft of the manuscript. YzL and JZ organized the database. DS and JY performed the data curation and visualization. KY wrote sections of the manuscript. YiL and QG contributed to conception and design of the study. All authors contributed to manuscript revision, read, and approved the submitted version.

Funding

The present study was funded by Medical scientific research project of Health Commission of Hebei Province (No. 20231661) and Medical scientific research project of Health Commission of Hebei Province (No. 20231649).

Acknowledgments

We thank the patients and their families for their participation in this study.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

  • 1

    AlfadhelM.UmairM.AlmuzzainiB.AlsaifS.AlMohaimeedS. A.AlmasharyM. A.et al (2019). Targeted SLC19A3 gene sequencing of 3000 Saudi newborn: A pilot study toward newborn screening. Ann. Clin. Transl. neurology6 (10), 2097–2103. 10.1002/acn3.50898

  • 2

    AlyafeeY.Al TuwaijriA.AlamQ.UmairM.HaddadS.AlharbiM.et al (2021). Next generation sequencing based non-invasive prenatal testing (NIPT): First report from Saudi Arabia. Front. Genet.12, 630787. 10.3389/fgene.2021.630787

  • 3

    AlyafeeY.Al TuwaijriA.UmairM.AlharbiM.HaddadS.BallowM.et al (2022). Non-invasive prenatal testing for autosomal recessive disorders: A new promising approach. Front. Genet.13, 1047474. 10.3389/fgene.2022.1047474

  • 4

    AlyafeeY.AlamQ.TuwaijriA. A.UmairM.HaddadS.AlharbiM.et al (2021). Next-generation sequencing-based pre-implantation genetic testing for aneuploidy (PGT-A): First report from Saudi Arabia. Genes12 (4), 461. 10.3390/genes12040461

  • 5

    BaujatG.HuberC.El HokayemJ.CaumesR.Do Ngoc ThanhC.DavidA.et al (2013). Asphyxiating thoracic dysplasia: Clinical and molecular review of 39 families. J. Med. Genet.50 (2), 91–98. 10.1136/jmedgenet-2012-101282

  • 6

    BonafeL.Cormier-DaireV.HallC.LachmanR.MortierG.MundlosS.et al (2015). Nosology and classification of genetic skeletal disorders: 2015 revision. Am. J. Med. Genet. Part A167a (12), 2869–2892. 10.1002/ajmg.a.37365

  • 7

    CarterA. P.ChoC.JinL.ValeR. D. (2011). Crystal structure of the dynein motor domain. Sci. (New York, NY)331 (6021), 1159–1165. 10.1126/science.1202393

  • 8

    ChenC. P.ChangT. Y.ChenC. Y.WangT. Y.TsaiF. J.WuP. C.et al (2012). Short rib-polydactyly syndrome type II (majewski): Prenatal diagnosis, perinatal imaging findings and molecular analysis of the NEK1 gene. Taiwan. J. obstetrics Gynecol.51 (1), 100–105. 10.1016/j.tjog.2012.01.020

  • 9

    ChenC. P.ChangT. Y.TzenC. Y.LinC. J.WangW. (2002). Sonographic detection of situs inversus, ventricular septal defect, and short-rib polydactyly syndrome type III (Verma-Naumoff) in a second-trimester fetus not known to be at risk. Ultrasound obstetrics Gynecol.19, 629. 10.1046/j.1469-0705.2002.00731_4.x

  • 10

    ChenC. P.ChangT. Y.TzenC. Y.WangW. (2003). Second-trimester sonographic detection of short rib-polydactyly syndrome type II (Majewski) following an abnormal maternal serum biochemical screening result. Prenat. Diagn.23, 353. 10.1002/pd.574

  • 11

    ChenC. P.ChernS. R.ChangT. Y.SuY. N.ChenY. Y.SuJ. W.et al (2012). Prenatal diagnosis and molecular genetic analysis of short rib-polydactyly syndrome type III (Verma-Naumoff) in a second-trimester fetus with a homozygous splice site mutation in intron 4 in the NEK1 gene. Taiwan. J. obstetrics Gynecol.51 (2), 266–270. 10.1016/j.tjog.2012.04.018

  • 12

    ChenC. P.KoT. M.ChangT. Y.ChernS. R.ChenS. W.LaiS. T.et al (2018). Prenatal diagnosis of short-rib polydactyly syndrome type III or short-rib thoracic dysplasia 3 with or without polydactyly (SRTD3) associated with compound heterozygous mutations in DYNC2H1 in a fetus. Taiwan. J. obstetrics Gynecol.57 (1), 123–127. 10.1016/j.tjog.2017.12.021

  • 13

    ChenC. P.ShihJ. C.TzenC. Y.LinY. H.WangW. (2005). Recurrent short-rib polydactyly syndrome: Prenatal three-dimensional ultrasound findings and associations with congenital high airway obstruction and pyelectasia. Prenat. Diagn.25 (5), 417–418. 10.1002/pd.976

  • 14

    ChenC. P.TzenC. Y. (2001). Short-rib polydactyly syndrome type III (Verma-Naumoff) in a third-trimester fetus with unusual associations of epiglottic hypoplasia, renal cystic dysplasia, pyelectasia and oligohydramnios. Prenat. Diagn.21, 1101. 10.1002/pd.182

  • 15

    ChenL. S.ShiS. J.ZouP. S.MaM.ChenX. H.CaoD. H. (2016). Identification of novel DYNC2H1 mutations associated with short rib-polydactyly syndrome type III using next-generation panel sequencing. Genet. Mol. Res. GMR15 (2). 10.4238/gmr.15028134

  • 16

    ChoC.Reck-PetersonS. L.ValeR. D. (2008). Regulatory ATPase sites of cytoplasmic dynein affect processivity and force generation. J. Biol. Chem.283 (38), 25839–25845. 10.1074/jbc.M802951200

  • 17

    DagoneauN.GouletM.GenevièveD.SznajerY.MartinovicJ.SmithsonS.et al (2009). DYNC2H1 mutations cause asphyxiating thoracic dystrophy and short rib-polydactyly syndrome, type III. Am. J. Hum. Genet.84 (5), 706–711. 10.1016/j.ajhg.2009.04.016

  • 18

    HuberC.Cormier-DaireV. (2012). Ciliary disorder of the skeleton. Am. J. Med. Genet. Part C, Seminars Med. Genet.160c (3), 165–174. 10.1002/ajmg.c.31336

  • 19

    KrakowD.SalazarD.WilcoxW. R.RimoinD. L.CohnD. H. (2000). Exclusion of the Ellis-van Creveld region on chromosome 4p16 in some families with asphyxiating thoracic dystrophy and short-rib polydactyly syndromes. Eur. J. Hum. Genet. EJHG8 (8), 645–648. 10.1038/sj.ejhg.5200507

  • 20

    McInerney-LeoA. M.HarrisJ. E.LeoP. J.MarshallM. S.GardinerB.KinningE.et al (2015). Whole exome sequencing is an efficient, sensitive and specific method for determining the genetic cause of short-rib thoracic dystrophies. Clin. Genet.88 (6), 550–557. 10.1111/cge.12550

  • 21

    MerrillA. E.MerrimanB.Farrington-RockC.CamachoN.SebaldE. T.FunariV. A.et al (2009). Ciliary abnormalities due to defects in the retrograde transport protein DYNC2H1 in short-rib polydactyly syndrome. Am. J. Hum. Genet.84 (4), 542–549. 10.1016/j.ajhg.2009.03.015

  • 22

    PazourG. J.AgrinN.WalkerB. L.WitmanG. B. (2006). Identification of predicted human outer dynein arm genes: Candidates for primary ciliary dyskinesia genes. J. Med. Genet.43 (1), 62–73. 10.1136/jmg.2005.033001

  • 23

    RakhshaniH.DehghanianE.RahatiA. (2019). Enhanced GROMACS: Toward a better numerical simulation framework. J. Mol. Model.25 (12), 355. 10.1007/s00894-019-4232-z

  • 24

    RichardsS.AzizN.BaleS.BickD.DasS.Gastier-FosterJ.et al (2015). Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. Genet. Med.17 (5), 405–424. 10.1038/gim.2015.30

  • 25

    SchmidtH.ZalyteR.UrnaviciusL.CarterA. P. (2015). Structure of human cytoplasmic dynein-2 primed for its power stroke. Nature518 (7539), 435–438. 10.1038/nature14023

  • 26

    SchmidtsM.ArtsH. H.BongersE. M.YapZ.OudM. M.AntonyD.et al (2013). Exome sequencing identifies DYNC2H1 mutations as a common cause of asphyxiating thoracic dystrophy (Jeune syndrome) without major polydactyly, renal or retinal involvement. J. Med. Genet.50 (5), 309–323. 10.1136/jmedgenet-2012-101284

  • 27

    SchmidtsM.VodopiutzJ.Christou-SavinaS.CortésC. R.McInerney-LeoA. M.EmesR. D.et al (2013). Mutations in the gene encoding IFT dynein complex component WDR34 cause Jeune asphyxiating thoracic dystrophy. Am. J. Hum. Genet.93 (5), 932–944. 10.1016/j.ajhg.2013.10.003

  • 28

    Soteras GutiérrezI.LinF. Y.VanommeslaegheK.LemkulJ. A.ArmacostK. A.BrooksC. L.3rdet al (2016). Parametrization of halogen bonds in the CHARMM general force field: Improved treatment of ligand-protein interactions. Bioorg. Med. Chem.24 (20), 4812–4825. 10.1016/j.bmc.2016.06.034

  • 29

    ToropovaK.ZalyteR.MukhopadhyayA. G.MladenovM.CarterA. P.RobertsA. J. (2019). Structure of the dynein-2 complex and its assembly with intraflagellar transport trains. Nat. Struct. Mol. Biol.26 (9), 823–829. 10.1038/s41594-019-0286-y

  • 30

    ZhangJ.HuH.MuW.YuM.ChenW.MiD.et al (2021). Case report: Exome sequencing identified a novel compound heterozygous variation in PLOD2 causing bruck syndrome type 2. Front. Genet.12, 619948. 10.3389/fgene.2021.619948

  • 31

    ZhangW.TaylorS. P.EnnisH. A.ForlenzaK. N.DuranI.LiB.et al (2018). Expanding the genetic architecture and phenotypic spectrum in the skeletal ciliopathies. Hum. Mutat.39 (1), 152–166. 10.1002/humu.23362

Summary

Keywords

DYNC2H1 gene, short-rib thoracic dysplasia 3 (SRTD3), skeletal dysplasia, whole-exome sequencing, prenatal diagnosis

Citation

Chen W, Li Y, Zhang J, Yuan Y, Sun D, Yuan J, Yang K, Liang Y and Guo Q (2023) Genetic variations in the DYNC2H1 gene causing SRTD3 (short-rib thoracic dysplasia 3 with or without polydactyly). Front. Genet. 14:1125473. doi: 10.3389/fgene.2023.1125473

Received

16 December 2022

Accepted

27 March 2023

Published

06 April 2023

Volume

14 - 2023

Edited by

Hu Hao, The Sixth Affiliated Hospital of Sun Yat-sen University, China

Reviewed by

Nadia Akawi, United Arab Emirates University, United Arab Emirates

Muhammad Umair, King Abdullah International Medical Research Center (KAIMRC), Saudi Arabia

Updates

Copyright

*Correspondence: Qing Guo, ; Ying Liang,

† These authors have contributed equally to this work and share first authorship

This article was submitted to Genetics of Common and Rare Diseases, a section of the journal Frontiers in Genetics

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics